Our Leadership

Kevin Barnett

General Manager

Kevin BarnettGeneral Manager at Promidian, Kevin has served as a strategic advisor to leading life sciences companies for nearly two decades. His consulting expertise spans a broad array of areas including corporate strategy, portfolio and product strategy, pricing and market access, and operational effectiveness.

Prior to joining Promidian, Kevin held senior leadership roles with Leerink Swann and Campbell Alliance. At Campbell Alliance, Kevin served as Global Practice Area Leader for the firm’s Pricing and Market Access Practice. He also held management consulting positions at Deloitte Consulting and Mattson Jack Group. Before his career in consulting, Kevin worked in various commercial roles with The Upjohn Company.

Kevin has authored numerous articles and presented at myriad industry conferences on key strategic issues facing the pharmaceutical and biotechnology industries. He has been quoted and referenced in leading business publications and industry trade journals including BusinessWeek, The Pink SheetThe RPM Report, Pharmaceutical ExecutiveMedAdNews, PharmaVOICE, and Managed Healthcare Executive. 

Kevin holds a bachelor of science degree in bioengineering from Purdue University and a master of business administration degree from Indiana University’s Kelley School of Business.

Jeff Liepman

Senior Managing Director

Jeff LiepmanJeff is a senior managing director at Promidian and a life sciences consulting veteran, bringing over a decade of analytical, strategic, and operational experience to the company. He has focused primarily on supporting top-tier pharma and biotech executives with brand and portfolio strategy, commercial effectiveness, business development, and market access optimization.

Jeff oversees Promidian’s west coast business, having built both the Los Angeles and San Francisco offices from the ground up. He has led several hundred consulting projects over the years for clients around the globe and has been a strategic thought partner to them on a wide array of specialized topics, including biosimilars, companion diagnostics, immuno-oncology, precision medicine, and rare disease strategy.

Before joining Promidian, Jeff was senior vice president and regional general manager for Campbell Alliance (now part of Syneos Health), where he was responsible for consulting operations throughout the southwestern United States. Prior to his career in consulting, Jeff served as a business development associate with Amylin Pharmaceuticals (since acquired by Bristol-Myers Squibb).

A life sciences thought leader, Jeff has hosted industry webinars, authored a variety of journal articles and white papers, presented at several biotech leadership conferences, and guest lectured at a number of universities and graduate schools.

Jeff received his bachelor of science degree in biochemistry from Willamette University in Salem, Oregon. He also has a master of bioscience (MSc and MBA) degree, with a specialty focus in the business of bioscience, from the Keck Graduate Institute of Applied Life Sciences in Claremont, California.

Faruk Abdullah

Managing Director

Faruk Abdullah, managing director at Promidian, is a life sciences professional who has spent the last decade of his career helping clients address a broad range of strategic issues including corporate development, portfolio planning, and launch excellence.

Prior to joining Promidian, Faruk was a vice president at Applied Predictive Technologies (APT). Faruk led the Life Sciences and Healthcare practice at APT, where he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data. Before joining APT, Faruk was an associate partner at the Monitor Group, where he focused on shaping and executing strategic initiatives for large and mid-cap life science companies. In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts developing products in both the therapeutic and medical device spaces.

Faruk has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem. He also has offered insights on how organizations can rethink how to develop and integrate analytic capabilities to inform critical strategic decisions.

Faruk holds a bachelor of science degree in electrical engineering from Northwestern University and an MBA from Harvard Business School.

Ed Corbett

Senior Principal

Ed Corbett, Senior Principal at Promidian, leads the EMEA practice. He has worked in the pharmaceutical industry for nearly two decades as both a consultant and a pharmaceutical executive. He is an expert in commercial and corporate strategy and has significant launch experience, having personally led four launches during his time as a pharmaceutical executive.

Working with a diverse set of clients from big pharma to biotech, Ed has helped these organizations address a range of problems, including route-to-market strategy, US and EU entry strategy, EU launch excellence, and portfolio optimization.

Prior to Promidian, Ed was a Partner at the boutique pharmaceutical consultancy Novasecta, where he supported clients with commercial and corporate strategy challenges. Before becoming a consultant, he spent 14 years working at both MSD/Merck and GSK, starting as a sales representative before moving into increasingly senior commercial roles at the local and global level.

Ed has been a featured speaker on such topics as patient centricity and the use of artificial intelligence in the pharmaceutical industry. He is also a frequent commentator on the pharma industry, with his views sought by international news outlets such as Bloomberg.

Ed holds an MA in biological sciences from Brasenose College, University of Oxford. He is also a Lean Six Sigma Black Belt and is PRINCE2 project management qualified.

Adam Giblin

Senior Principal

Adam Giblin, Senior Principal at Promidian, is a commercial strategy leader with more than a decade of experience shaping and executing insight-driven strategy in the life sciences, as both a consultant and an executive in the industry.

Prior to joining Promidian, Adam worked in the global commercial organization for the diagnostics division of Abbott Laboratories, most recently as the global launch lead for diagnostics systems. Prior to Abbott, he spent a decade as a strategy consultant for the Monitor Group (later acquired by Deloitte), where he served pharma, biotech, and device leaders in making critical decisions about strategy at both the corporate and commercial levels.

As an expert on future commercial models in the life sciences, Adam has had a particular focus on customer-centered strategy and analytics. He has extensive experience in all aspects of customer-centered marketing, including customer analytics and segmentation, campaign design, marketing automation, and data integration. He also has considerable experience in the US and major European markets and has played a variety of roles related to corporate and commercial strategy, with an emphasis on business unit strategy, product development and launch strategy, and financial decision-making.

Adam has authored and contributed to numerous articles on the use of advanced analytics and insight generation. In addition, he has been a featured speaker on a range of topics, including the role of analytics in life sciences strategy.

Adam holds an MBA with distinction in marketing, finance, and health enterprise management from the Kellogg School of Management at Northwestern University and a BS in foreign service, magna cum laude, from Georgetown University.

Jonathan Hodgson

Senior Principal

JonathanHodgsonA Senior Principal with Promidian, Jonathan has more than 15 years of experience helping biopharmaceutical companies make better strategic decisions in the areas of commercialization, R&D, portfolio planning, launch pricing and reimbursement, forecasting, asset valuation, and more across a broad range of therapeutic areas.

Jonathan’s experience spans both commercial and market access questions, and the development and application of both quantitative and qualitative insights. As such, he brings particularly deep expertise in leveraging innovative methodologies and large data sets to support analysis and strategic decision-making.

Before joining Promidian, Jonathan served as Principal at Putnam Associates, where he contributed to the growth of the firm’s New Products Strategy and Pricing, Reimbursement and Market Access practices. As Senior Principal at the Amundsen Group, Jonathan blended insights from large quantitative data sets with qualitative and secondary research to drive actionable recommendations for clients. He also previously served as a strategy consultant at L.E.K. Consulting, where he was largely focused on forecasting and valuation, as well as asset screens and business development strategy for smaller biotech companies. Jonathan has also served in several roles at Vertex Pharmaceuticals.

Jonathan has lectured on valuation approaches and techniques at the Massachusetts Biotechnology Council, and he is co-author of “Biopharma: Beyond the First Product,” an in-depth look at critical success factors for growth of emerging biotechs, published in In Vivo. He also has written several white papers on trending topics in pricing and market access.

Jonathan earned a bachelor of arts in economics from Dartmouth College and an MBA from Harvard Business School.

Molly Hoult

Senior Principal

Molly Hoult Molly Hoult is a Senior Principal with Promidian and an expert at helping life science companies build value by meeting market needs better than their competitors. She digs deep into market and competitive dynamics to determine how best to develop a product, enter a market, and expand into new areas to accelerate growth.

Delivering actionable recommendations to management, boards of directors, and investors, Molly has been a strategic partner to biopharma, diagnostics, and device companies of all sizes for over 15 years. Her experience spans commercial strategy, new product planning, market research, business and corporate development, project management, and more across major therapeutic areas and US and ex-US markets.

Before joining Promidian, Molly was Senior Vice President in the Life Science Practice at Fletcher Spaght, Inc., where she had a strong track record of achieving high client satisfaction, delivering projects on time and on budget, and mentoring junior staff. Over her decade there, Molly led many cross-functional teams in conducting primary market research and analyses of market size, growth, trends, competitive landscapes, receptivity, pricing, reimbursement, segmentation, distribution options, revenue analysis, and valuation.

Prior to Fletcher Spaght, Molly was an independent consultant providing strategic planning and business development services to life science companies. Before that, she was a Senior Vice President at Blue Heron Biotechnology, where she launched a DNA synthesis service and built the organization’s commercial team. Molly has also held senior business development positions at XCyte Therapies and ZymoGenetics (now part of Bristol-Myers Squibb) and has been a Product Manager at NeoPath (now part of BD Diagnostics) and Amgen.

Molly holds an MBA from Stanford Graduate School of Business, where she was an Arjay Miller Scholar, and a bachelor of arts with honors in biology and a minor in environmental studies from Dartmouth College.

Sean Rapson

Senior Principal

Sean Rapson A Senior Principal with Promidian, Sean brings more than a decade of experience in the industry and a unique perspective to engagements gained through various internal commercial roles at a premier biopharmaceutical company and as a consultant advising leading biopharmaceutical clients.
Sean’s focus is on defining and delivering vision and strategy at the corporate, portfolio, and brand levels while taking into account both the evolving stakeholder dynamics in the US biopharmaceutical market as well as digital capabilities that are rapidly transforming how biopharmaceutical companies develop therapies, commercialize brands, engage stakeholders, and generate and act on insights.

His collaborative approach helps clients innovatively define vision and strategy and flawlessly execute transformative programs that address people, process, technology, and data capabilities using a collection of methodologies, working session designs, facilitation techniques, and a proven approach to change management.

His expertise has been instrumental in helping clients solve challenges through brand commercialization and launch, digital medicine development and commercialization, late-stage loss-of-exclusivity marketing strategy development, health system customer marketing development, innovation programs, digital closed-loop multi-channel marketing transformations with analytics capabilities, and drug delivery device market scans.

Sean earned a bachelor of commerce from Monash University (Australia), with majors in econometrics, analytics, and marketing strategy.

Chien Sun, PhD

Senior Principal

ChienSun With a strong background in Biomedical Engineering, Chien Sun, Senior Principal, has been advising life science clients on product launch, market access strategy, growth strategy, and life cycle management for many years. He has particular expertise in cancer therapeutics, diagnostics, and nanotechnology.

Prior to joining Promidian, Chien consulted in the life sciences division at L.E.K. Consulting and led engagements that spanned landscape assessment, value-maximizing strategy, growth strategy, and asset evaluation for leading pharmaceutical and diagnostics companies.

Chien previously was the Chief Operating Officer for The Center for Cell Control, a regional Nanomedicine Development Center funded by the National Institutes of Health, where he led a multi-institutional team of researchers from the University of California at Los Angeles, University of California at Berkeley, and Stanford University. He also founded and served as Chief Research and Development Officer for Synlixir Therapeutics, a biotech startup focused on developing combination therapies for early-stage cancers.

Chien received his MS (instrumentation and sensors) and PhD (cancer therapeutics) in biomedical engineering from the University of California at Los Angeles where he was the recipient of the Outstanding MS Award and the Outstanding PhD Award at graduation. As a postdoctoral scholar at UCLA, he developed a novel patented multi-drug platform for the treatment of cancer, eradication of infection, and the differentiation of stem cells. Chien additionally holds a bachelor’s degree in biological sciences from the University of California at Irvine where he graduated Phi Beta Kappa along with other high honors.